Real-world outcomes comparing the use of GLP-1 agonists in patients with colon cancer and comorbid obesity: A propensity score matched analysis from Global Federated Health Research Network.

83 Background: Colon cancer is among the leading causes of cancer-related morbidity and mortality globally, with an increasing incidence observed in younger populations. Lifestyle and metabolic risk factors seem to play an important role in this rising incidence. Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used for the treatment of type 2 diabetes and obesity. Emerging evidence suggests that these agents may have potential anti-tumor activity as GLP-1 signaling may influence pathways involved in cell proliferation and inflammation. Our study aims to evaluate the impact of GLP-1 receptor agonists on outcomes among patients with colon cancer with comorbid obesity, exploring potential interactions between metabolic modulation and disease behavior. Methods: A retrospective cohort study was conducted using the US Collaborative Network TriNetX, covering January 2000 to December 2023, encompassing data from 105 global healthcare organizations. Adult patients aged 18 and above with colon cancer and comorbid obesity were identified and then stratified into two groups based on treatment with GLP-1 agonists or not. The two groups were then propensity-matched based on age, sex, race, and common comorbidities. We followed these patients for 5 years to assess outcomes, including overall mortality, myocardial infarction, sepsis, acute pancreatitis, need for mechanical ventilation and hemodialysis. Results: We identified 1986 patients with colon cancer and obesity who received GLP-1 receptor agonists, and 16384 patients with colon cancer and obesity who did not receive GLP-1 therapy. The average age was 68.8 years in the first cohort and 74.3 years in the second cohort. After propensity matching, each cohort consisted of 1983 patients with similar baseline characteristics and ethnicity distribution. Our analysis found that over 5 years, patients with colon cancer and obesity who received GLP-1 receptor agonists had a significantly lower risk of overall mortality (Hazard Ratio (HR): 0.461, 95% CI: 0.401 to 0.532, p-value < 0.001), myocardial infarction (HR: 0.827, 95% CI: 0.668 to 0.993, p-value =0.005), sepsis (Risk Difference: -3.48%, 95% CI: -4.774 to -2.185, p-value < 0.001), and need for mechanical ventilation (HR: 0.486, 95% CI: 0.321 to 0.739, p-value = 0.037). There was no statistically significant difference in the risk of acute pancreatitis and need for hemodialysis between the two subgroups. Conclusions: Our study revealed that patients with colon cancer and obesity who received GLP-1 receptor agonists had a significantly lower risk of mortality, myocardial infarction, sepsis, and need for mechanical ventilation. Further longitudinal cohort studies are imperative to better understand these associations and guide evidence-based clinical practice in this population.